Spread the love

A recent study from the Department of Radiation Oncology, Cancer Institute and Institute for Stem Cell Biology and Regenerative Medicine, Department of Otolaryngology (Head and Neck Surgery), and Department of Pathology, Stanford University School of Medicine, Stanford, California, USA has reported that Neurotrophic factor GDNF promotes survival of salivary stem cells. This study was published in the August 1 2014 Journal Clinical Investigation (The number 1 journal in Clinical General Medicine) by Prof  Le QT,  Xiao, and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMDreports that: Insights into Anticancer drug-induced Xerostomia: Campothecin (CPT) inhibits survival of salivary stem cells via up regulation of its target genes. This study suggests that Campothecin (CPT), by inducing the expression of a number of tumor suppressor genes, including p53, it could  inhibit the survival of Salivary stem cells and saliva secretion.  Furthermore, this study, for the first time, explains why cancer patients taking anti-cancer drugs suffer from Xerostomia. Together, this study provides mechanistic insights into how anticancer drugs promote Xerostomia.

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

CitationBoominathan, Insights into Anticancer drug-induced Xerostomia: Campothecin (CPT) inhibits survival of salivary stem cells via up regulation of its target genes 12/August/2014, 10.53 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Significance: This study provides molecular insights into how anti-cancer drugs promote Xerostomia.

 * Research cooperation

Spread the love